Identifying SETBP1 haploinsufficiency molecular pathways to improve patient diagnosis using induced pluripotent stem cells and neural disease modelling.
Nicole C Shaw, Kevin Chen, Kathryn O Farley and 5 others
PMID 39350244WHAT IT FOUND
A variant of unknown significance in the SETBP1 gene caused neural cell defects matching those of known pathogenic mutations.
This suggests such variants should be treated as likely disease-causing rather than uncertain when assessing patients.
Key findings
01A single nucleotide variant currently classified as a variant of unknown significance (VUS2) produced neural cell differentiation defects similar to those caused by known pathogenic truncation mutations.
02The disease-like cells showed disrupted WNT/beta-catenin signalling and a key role for the transcription factor GATA2, pathways involved in forebrain development.
03562 of 1444 SETBP1 variants in the ClinVar database are currently classified as variants of unknown significance, creating a diagnostic bottleneck.
STILL TO COME
How it was doneWhat they foundWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study used cells in a dish (iPSC-derived neural progenitors), not living patients, so it cannot confirm clinical outcomes or treatment responses. Neural progenitor cells are an early stage of brain development; the study did not use mature neurons or brain organoids, which might show different or more complex deficits. The number of cell lines tested was small (three clones per variant type), and findings rely on molecular patterns rather than functional neural activity.
Declared interests
The study was funded by the Western Australia Department of Health, Trialect Orphan Disease Center, Million Dollar Bike Ride, Stan Perron Charitable Foundation, and Feilman Foundation. No commercial conflicts of interest were declared.
The easy way to misread this
Do not assume this paper proves a new treatment or that the VUS variant is definitively pathogenic in every patient. It provides molecular evidence from cells in a lab that the variant behaves like known disease-causing mutations, but clinical confirmation requires further study and should not override current diagnostic guidelines without specialist input.